Sangamo Therapeutics, Inc. (LON:0R1D)
London
· Delayed Price · Currency is GBP · Price in USD 0.5436
+0.0037 (0.69%)
At close: Jul 2, 2025
Sangamo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 63.76 | 57.8 | 176.23 | 111.3 | 110.7 | 118.19 | Upgrade
| |
Revenue Growth (YoY) | 239.92% | -67.20% | 58.34% | 0.54% | -6.34% | 15.39% | Upgrade
|
Cost of Revenue | 101.63 | 111.52 | 230.46 | 249.9 | 230.82 | 180.65 | Upgrade
|
Gross Profit | -37.88 | -53.72 | -54.23 | -138.6 | -120.12 | -62.46 | Upgrade
|
Selling, General & Admin | 42.92 | 44.63 | 60.07 | 62.68 | 63.22 | 67.1 | Upgrade
|
Operating Expenses | 42.92 | 44.63 | 60.07 | 62.68 | 63.22 | 67.1 | Upgrade
|
Operating Income | -80.8 | -98.35 | -114.29 | -201.28 | -183.34 | -129.55 | Upgrade
|
Interest & Investment Income | 8.06 | 8.2 | 8.25 | 6.43 | 5.35 | 8.78 | Upgrade
|
Currency Exchange Gain (Loss) | -2.94 | -2.94 | 2.85 | - | - | - | Upgrade
|
EBT Excluding Unusual Items | -78.92 | -93.09 | -103.19 | -194.85 | -177.99 | -120.78 | Upgrade
|
Merger & Restructuring Charges | -0.1 | -0.1 | -4.7 | - | - | - | Upgrade
|
Impairment of Goodwill | - | - | -38.14 | - | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | 0.6 | 0.6 | - | - | - | - | Upgrade
|
Asset Writedown | -1.17 | -5.52 | -116.88 | - | - | - | Upgrade
|
Other Unusual Items | - | - | - | 3 | - | - | Upgrade
|
Pretax Income | -79.6 | -98.11 | -262.9 | -191.85 | -177.99 | -120.78 | Upgrade
|
Income Tax Expense | -0.15 | -0.17 | -5.07 | 0.43 | 0.31 | 0.35 | Upgrade
|
Earnings From Continuing Operations | -79.45 | -97.94 | -257.83 | -192.28 | -178.3 | -121.12 | Upgrade
|
Minority Interest in Earnings | - | - | - | - | 0.01 | 0.13 | Upgrade
|
Net Income | -79.45 | -97.94 | -257.83 | -192.28 | -178.29 | -121 | Upgrade
|
Net Income to Common | -79.45 | -97.94 | -257.83 | -192.28 | -178.29 | -121 | Upgrade
|
Shares Outstanding (Basic) | 212 | 202 | 174 | 154 | 145 | 134 | Upgrade
|
Shares Outstanding (Diluted) | 212 | 202 | 174 | 154 | 145 | 134 | Upgrade
|
Shares Change (YoY) | 19.33% | 15.62% | 13.02% | 6.76% | 7.53% | 19.92% | Upgrade
|
EPS (Basic) | -0.38 | -0.49 | -1.48 | -1.25 | -1.23 | -0.90 | Upgrade
|
EPS (Diluted) | -0.38 | -0.49 | -1.48 | -1.25 | -1.23 | -0.90 | Upgrade
|
Free Cash Flow | -44.89 | -67.41 | -246 | -243.8 | -256.53 | 155.16 | Upgrade
|
Free Cash Flow Per Share | -0.21 | -0.33 | -1.41 | -1.58 | -1.77 | 1.15 | Upgrade
|
Gross Margin | -59.41% | -92.94% | -30.77% | -124.53% | -108.51% | -52.84% | Upgrade
|
Operating Margin | -126.73% | -170.15% | -64.85% | -180.85% | -165.62% | -109.61% | Upgrade
|
Profit Margin | -124.61% | -169.45% | -146.30% | -172.76% | -161.05% | -102.37% | Upgrade
|
Free Cash Flow Margin | -70.41% | -116.62% | -139.59% | -219.05% | -231.73% | 131.28% | Upgrade
|
EBITDA | -76.08 | -93.24 | -99.23 | -189.17 | -173.9 | -123.87 | Upgrade
|
EBITDA Margin | -119.32% | -161.32% | -56.31% | -169.97% | -157.09% | -104.80% | Upgrade
|
D&A For EBITDA | 4.72 | 5.11 | 15.07 | 12.11 | 9.44 | 5.68 | Upgrade
|
EBIT | -80.8 | -98.35 | -114.29 | -201.28 | -183.34 | -129.55 | Upgrade
|
EBIT Margin | -126.73% | -170.15% | -64.85% | -180.85% | -165.61% | -109.61% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.